BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
April 16, 2024 07:45 ET
|
BioRestorative Therapies, Inc
— Amendment replaces saline injections with sham injections in the control group — MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or...
MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis
December 14, 2022 08:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis Phase 2 study represents an important step in psoriatic arthritis...
Sermonix Pharmaceuticals Announces Four Abstracts Accepted for Presentation at 2022 San Antonio Breast Cancer Symposium
November 17, 2022 09:00 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative targeted therapeutics to specifically treat...
MATEON’S C001- A GLOBAL PHASE 2 STUDY FOR OT-101 AGAINST COVID-19- RECEIVED CLEARANCE FOR PATIENT ENROLLMENT
November 04, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announced today the receipt of approval from Instituto Nacional de Salud...
PROCESSA PHARMACEUTICALS ANNOUNCES RESULTS FROM THE PHASE 2 STUDY IN NECROBIOSIS LIPOIDICA
March 17, 2020 09:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, March 17, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in May
May 15, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 15, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating...
VBI Vaccines Announces Phase 2 Clinical Study Design of its Prophylactic CMV Vaccine Candidate
December 20, 2018 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...